Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 8, 2015, Pages 1309-1316

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Kajiwara, Eiji ^j   Nomura, Hideyuki ^k   Kawano, Akira ^l   Takahashi, Kazuhiro ^b   Dohmen, Kazufumi ^c   Satoh, Takeaki ^m   Azuma, Koichi ^d   Nakamuta, Makoto ^e   Koyanagi, Toshimasa ^f   Kotoh, Kazuhiro ^g   Shimoda, Shinji ^h   Hayashi, Jun ⁱ  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b HAMANOMACHI HOSPITAL   (Japan)

^c CHIHAYA HOSPITAL   (Japan)

^d KYUSHU CENTRAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f Fukuoka City Hospital   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ Hara Doi Hospital   (Japan)

^j STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^k Shin Kokura Hospital   (Japan)

^l KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^m Kokura Medical Center   (Japan)

more..

Author keywords

Anemia; Hepatitis C virus; Inosine triphosphatase; Ribavirin; Simeprevir

Indexed keywords

HEMOGLOBIN; INOSINE TRIPHOSPHATE; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ALPHA INTERFERON; ENZYME INHIBITOR; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; VIRUS PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY (TOPIC); RISK; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

AGE FACTORS; AGED; ANEMIA; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OLIGOPEPTIDES; PYROPHOSPHATASES; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK; SEVERITY OF ILLNESS INDEX; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937434612     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12945     Document Type: Article

References (27)

1. Mohd Hanafiah K, Groeger J, Flaxman AD etal. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
2. Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-1150.
3. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
4. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
5. Furusyo N, Ogawa E, Nakamuta M etal. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J. Hepatol. 2013; 59: 205-212.
6. Ogawa E, Furusyo N, Kajiwara E etal. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J. Gastroenterol. Hepatol. 2012; 27: 1233-1240.
7. Ramachandran P, Fraser A, Agarwal K etal. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment. Pharmacol. Ther. 2012; 35: 647-662.
8. Ogawa E, Furusyo N, Nakamuta M etal. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J. Hepatol. 2013; 59: 667-674.
9. Lawitz E, Sulkowski MS, Ghalib R etal. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
10. Zeuzem S, Berg T, Gane E etal. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.
11. Hayashi N, Izumi N, Kumada H etal. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J. Hepatol. 2014; 61: 219-227.
12. Simmonds P, Alberti A, Alter HJ etal. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
13. TheFrench METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
14. Sterling RK, Lissen E, Clumeck N etal. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
15. Vallet-Pichard A, Mallet V, Nalpas B etal. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
16. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am. J. Epidemiol. 1999; 150: 327-333.
17. Zeuzem S, DeMasi R, Baldini A etal. Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. J. Hepatol. 2014; 60: 1112-1117.
18. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York: John Wiley & Sons, 2000; 162.
19. Fattovich G, Stroffolini T, Zagni I etal. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
20. Davis GL, Alter MJ, El-Serag H etal. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
21. Ogawa E, Furusyo N, Kajiwara E etal. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J. Hepatol. 2013; 58: 495-501.
22. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 2000; 20: 1-16.
23. Furusyo N, Ogawa E, Murata M etal. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J. Antimicrob. Chemother. 2014; 69: 483-490.
24. Ogawa E, Furusyo N, Nakamuta M etal. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment. Pharmacol. Ther. 2013; 38: 1076-1085.
25. Fellay J, Thompson AJ, Ge D etal. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
26. Ochi H, Maekawa T, Abe H etal. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-1197.
27. De Nicolò A, Boglione L, Ciancio A etal. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Antiviral Res. 2014; 109: 7-14.